Trial Profile

A Phase 1/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants With Advanced/Metastatic Solid Tumors.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MK 0472 (Primary) ; MK-1084 (Primary) ; Pembrolizumab (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Merck Sharp & Dohme

Most Recent Events

23 May 2024 Number of treatment arms are increased from 2 to 3 by the addition of Experimental: MK-0472 + MK-1084 arm.
23 May 2024 Planned number of patients changed from 100 to 178.
28 Jun 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com